Navigation Links
3SBio Inc. Announces Preliminary Third Quarter 2008 Results
Date:10/31/2008

pharmaceutical industry with Eli Lilly & Company and EMD Pharmaceuticals, Inc. in North America and went on to serve as a China healthcare and consumer analyst at Lehman Brothers Asia and Macquarie Securities in Hong Kong.

In addition, Kevin Teo will return to his role as the Company's Director of Finance, no longer serving as Chief Financial Officer of 3SBio. Mr. Teo will continue to be responsible for the Company's accounting and controlling functions. Mr. Tan will facilitate the search for an experienced and qualified replacement Chief Financial Officer for 3SBio.

Dr. Jing Lou, Chief Executive Officer of 3SBio, commented, "While we continue to benefit from robust growth opportunities and increased demand for our products, we recognize the need to be especially prudent in the current macro environment. We are actively working to better manage our mark-to-market valuation levels and preserve our treasury and cash assets. We have formed an Investment Advisory Committee and are pleased to welcome Bo Tan to join our efforts in risk management and other initiatives. I am confident that the collaboration between these two parties will better align our investment portfolio allocations for the best interest of our shareholders."

"Despite the one-time impairment charge that adversely affected our bottom-line for the third quarter, 3SBio remains fundamentally strong. On the operational front, we continue to demonstrate market leadership within our core product areas and our pipeline drugs are on track for SFDA submission. From a financial perspective, we continue to deliver top line growth with a strong balance sheet and sufficient free cash flow. As we maintain our strategic focus and execute on our growth initiatives, we are confident in our ability to meet our full year total net revenue guidance of US$34 to US$35 million."

Conference Call

3SBio senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... KEEGO HARBOR, Mich. , Sept. 18, 2014  Health ... -based biotech firm investigating early-stage algae bioactive compounds and metabolic ... member to the company,s board of directors. Ms. Nola ... executive and investment advisor joined the board effective September 17, ... have Ms. Masterson agree to join our board," states ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... PVC-C, a FM-4910 listed material, to stay competitive ... industries. These high-performance materials ultimately impact product ... company’s President and owner. , Established in 1980 ... held strong as many fabricators have left the ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
Breaking Biology Technology:Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... of revenue growth ... 2007 Highlights: * Product ... SET pulse oximeter units increase 20% to 116,300 units, IRVINE, Calif., Feb. ... Measure-Through,Motion & Low Perfusion pulse oximetry, today announced its financial,results for both the ...
... Replidyne, Inc.,(Nasdaq: RDYN ) today announced its financial results ... Replidyne reported a net loss of $16.9 million for ... per basic and diluted common share,of $0.63 per share, compared ... and diluted common share, for the quarter ended December 31, ...
... Market Research,a global provider of pharmaceutical competitive intelligence ... critical strategic insight,for pharma and biotech companies with ... therapies., In this report, entitled MedPredict Thought ... global Thought Leader Panel,debates tough questions facing drug ...
Cached Biology Technology:Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 2Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 3Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 4Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 5Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 6Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 7Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 8Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 9Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 10Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 11Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results 12Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2
(Date:9/18/2014)... icy moon of Uranus, is one of the most ... Despite its relatively small size, Miranda appears to have ... the formation of at least three remarkable and unique ... These coronae are visible in Miranda,s southern hemisphere, and ... corona, the largest, has ridges and troughs with up ...
(Date:9/18/2014)... University and the Quebec government have discovered microplastics ... Journal of Fisheries and Aquatic Sciences . , ... or industrial cleansers, to which they are commonly ... and buoyancy, they may readily pass through sewage ... in the world,s oceans, but have only recently ...
(Date:9/18/2014)... The fall foliage season that prompts millions of Americans to ... later and possibly last a little longer within a century, ... leaf peeping in some areas of the United States as ... report in the journal Global Ecology and Biogeography . ... that is the state tree of New Hampshire could ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... the laboratory of Assistant Professor Frank J. Slack at Yale ... is regulated in lung cancer, presenting new possibilities for diagnosis ... the journals Cell and Developmental Cell. , The oncogene Ras ... where it is over-expressed or activated by mutation. According to ...
... prevented allergic reactions in laboratory mice, as well as ... California, Los Angeles (UCLA) researchers report in the April ... future, the investigators say, these promising results could lead ... allergies, but also possibly for severe food allergies such ...
... dead bone of a transplanted skeletal graft into living tissue ... therapy to stimulate the body into treating the foreign splint ... of cancer and trauma patients each year who suffer with ... Feb. 13 and will appear in the March 1 issue ...
Cached Biology News:Yale Scientists Find MicroRNA Regulates Ras Cancer Gene 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 2Novel Therapy Tested in Mice Could Chase Away Cat Allergies 3Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4
Mouse monoclonal antibody raised against a partial recombinant PRKG1. NCBI Entrez Gene ID = PRKG1...
... polyclonal antibody raised against a ... Immunogen: PPP4C (NP_002711, ... partial recombinant protein with GST ... Number: NM_002720 ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Biology Products: